Rapid, scalable assay of amylin-β amyloid co-aggregation in brain tissue and blood

Kotiya, Deepak; Leibold, Noah; Verma, Nirmal; Jicha, Gregory A.; Goldstein, Larry B.; Despa, Florin

doi:10.1016/j.jbc.2023.104682

Cited by 5 publications

(1 citation statement)

References 44 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it has a wide range of applications, namely clinical diagnosis, biomedical research, food quality management, and environmental monitoring [ 42 ]. Especially, electrochemical sensors are compatible with miniaturized devices, which are appropriate for detecting biomarkers with an ultra-low concentration in human serum [ 43 , 44 ], saliva [ 45 , 46 ], blood [ 47 , 48 ], CSF [ 49 , 50 ], and plasma [ 51 , 52 , 53 ]. The operation of Aβ-based electrochemical sensors related to AD has been reported by a significant number of scientists obtaining high sensitivity and selectivity.…”

Section: Introductionmentioning

confidence: 99%

SAM-Support-Based Electrochemical Sensor for Aβ Biomarker Detection of Alzheimer’s Disease

Kim

Cho

2023

Biosensors

View full text Add to dashboard Cite

Alzheimer’s disease has taken the spotlight as a neurodegenerative disease which has caused crucial issues to both society and the economy. Specifically, aging populations in developed countries face an increasingly serious problem due to the increasing budget for patient care and an inadequate labor force, and therefore a solution is urgently needed. Recently, diverse techniques for the detection of Alzheimer’s biomarkers have been researched and developed to support early diagnosis and treatment. Among them, electrochemical biosensors and electrode modification proved their effectiveness in the detection of the Aβ biomarker at appropriately low concentrations for practice and point-of-care application. This review discusses the production and detection ability of amyloid beta, an Alzheimer’s biomarker, by electrochemical biosensors with SAM support for antibody conjugation. In addition, future perspectives on SAM for the improvement of electrochemical biosensors are also proposed and discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

SAM-Support-Based Electrochemical Sensor for Aβ Biomarker Detection of Alzheimer’s Disease

Kim

Cho

2023

Biosensors

View full text Add to dashboard Cite

show abstract

Neuroinflammation induced by amyloid-forming pancreatic amylin: Rationale for a mechanistic hypothesis

Leibold,

Despa

2024

Biophysical Chemistry

View full text Add to dashboard Cite

IAPP - oligomerisation levels in plasma of people with type 2 diabetes

Rehn,

Kraemer-Schulien,

Bujnicki

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Islet amyloid polypeptide (IAPP) is co-secreted with insulin from pancreatic ß-cells. Its oligomerisation is regarded as disease driving force in type 2 diabetes (T2D) pathology. Up to now, IAPP oligomers have been detected in affected tissues. IAPP oligomer concentrations in blood have not been analysed so far. Using the IAPP single-oligomer-sensitive and monomer-insensitive surface-based fluorescence intensity distribution analysis (sFIDA) technology, levels of IAPP oligomers in blood plasma from healthy controls and people with T2D in different disease stages where determined. Subsequently, the level of IAPP oligomerisation was introduced as the ratio between the IAPP oligomers determined with sFIDA and the total IAPP concentration determined with ELISA. Highest oligomerisation levels were detected in plasma of people with T2D without late complication and without insulin therapy. Their levels stand out significantly from the control group. Healthy controls presented with the lowest oligomerisation levels in plasma. In people with T2D without complications, IAPP oligomerisation levels correlated with disease duration. The results clearly demonstrate that IAPP oligomerisation in insulin-naïve patients correlates with duration of T2D. Although a correlation per se does not identify, which is cause and what is consequence, this result supports the hypothesis that IAPP aggregation is the driving factor of T2D development and progression. The alternative and conventional hypothesis explains development of T2D with increasing insulin resistance causing exhaustion of pancreatic ß-cells due to over-secretion of insulin, and thus IAPP, too, resulting in subsequent IAPP aggregation and fibril deposition in the pancreas. Further experiments and comparative analyses with primary tissues are warranted.

show abstract

Rapid, scalable assay of amylin-β amyloid co-aggregation in brain tissue and blood

Cited by 5 publications

References 44 publications

SAM-Support-Based Electrochemical Sensor for Aβ Biomarker Detection of Alzheimer’s Disease

SAM-Support-Based Electrochemical Sensor for Aβ Biomarker Detection of Alzheimer’s Disease

Neuroinflammation induced by amyloid-forming pancreatic amylin: Rationale for a mechanistic hypothesis

IAPP - oligomerisation levels in plasma of people with type 2 diabetes

Contact Info

Product

Resources

About